| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9bba0a34651fd8cd73cf83e6a9effe12 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 |
| filingDate |
1998-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7fd0321db4f154015ccb2b8e1d56b01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a7f98c3932da6d98dddf8feacf44ad4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd9d07b62280292b5c2086ef191a7126
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34a5e3d268c808b898e71a9e2aa29567 |
| publicationDate |
1999-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H11349488-A |
| titleOfInvention |
Immunosuppressants containing clusterin |
| abstract |
PROBLEM TO BE SOLVED: To provide an immunosuppressant having no side effects, which is useful for preventing rejection in organ / tissue transplantation or effective as a therapeutic agent for inflammatory diseases such as autoimmune diseases and allergic diseases. I will provide a. The present invention relates to an immunosuppressant containing clusterin. The clusterin may be derived from rat or / and human, and the peptide constituting clusterin may be subjected to pharmaceutically acceptable modification. |
| priorityDate |
1998-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |